Novacyt SA logo

NCYT - Novacyt SA Share Price

760p 43.0  6.0%

Last Trade - 25/11/20

Sector
Healthcare
Size
Mid Cap
Market Cap £529.4m
Enterprise Value £513.8m
Revenue £69.6m
Position in Universe 538th / 1803
Bullish
Bearish
Unlock NCYT Revenue
Momentum
Relative Strength (%)
1m -38.5%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -40.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
4.53 8.89 11.1 12.7 13.7 13.1 28.0 +23.6%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Novacyt SArevenues increased from EUR7.2M to EUR72.4M. Net incomeapplicable to common stockholders excluding extraordinaryitems totaled EUR40.2M vs. loss of EUR1.2M. Revenuesreflect Molecular screening segment increase from EUR3.3Mto EUR70.6M, Europe segment increase from EUR2.9M to EUR59M, Middle East (Region) segment increase from EUR815K toEUR4.2M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

NCYT Revenue Unlock NCYT Revenue

Net Income

NCYT Net Income Unlock NCYT Revenue

Normalised EPS

NCYT Normalised EPS Unlock NCYT Revenue

PE Ratio Range

NCYT PE Ratio Range Unlock NCYT Revenue

Dividend Yield Range

NCYT Dividend Yield Range Unlock NCYT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
NCYT EPS Forecasts Unlock NCYT Revenue
Profile Summary

Novacyt SA is a France-based company providing biotechnological solutions. The Company develops and markets solutions dedicated to the field of liquid-based cytology and molecular biology. The Company provides diagnostic products used in oncology, microbiology, haematology, and serology testing. The Company develops secure automated cytology named NovaPrep Processor System. Novacyt SA offers a solution of cytological sampling to help in the detection of precancerous and cancerous lesions. The Company creates bottles specifically dedicated to the optimization of cell collection. The Company’s range of products includes Bottle Gyn and No Gyn Bottle. Novacyt SA is present in France and internationally through a network of distributors.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated July 3, 2006
Public Since October 12, 2012
No. of Shareholders: n/a
No. of Employees: 110
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange London Stock Exchange (Dual Listing)
Shares in Issue 70,626,248
Free Float (0.0%)
Eligible for
ISAs
SIPPs
NCYT Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for NCYT
Upcoming Events for NCYT
Frequently Asked Questions for Novacyt SA
What is the Novacyt SA share price?

As of 25/11/20, shares in Novacyt SA are trading at 760p, giving the company a market capitalisation of £529.4m. This share price information is delayed by 15 minutes.

How has the Novacyt SA share price performed this year?

Shares in Novacyt SA are currently trading at 760p and the price has moved by 7.14k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Novacyt SA price has moved by 8.08k% over the past year.

What are the analyst and broker recommendations for Novacyt SA?

There are no analysts currently covering Novacyt SA.

When will Novacyt SA next release its financial results?

Novacyt SA is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Novacyt SA dividend yield?

Novacyt SA does not currently pay a dividend.

Does Novacyt SA pay a dividend?

Novacyt SA does not currently pay a dividend.

When does Novacyt SA next pay dividends?

Novacyt SA does not currently pay a dividend.

How do I buy Novacyt SA shares?

To buy shares in Novacyt SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Novacyt SA?

Shares in Novacyt SA are currently trading at 760p, giving the company a market capitalisation of £529.4m.

Where are Novacyt SA shares listed? Where are Novacyt SA shares listed?

Here are the trading details for Novacyt SA:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: NCYT
What kind of share is Novacyt SA?

Based on an overall assessment of its quality, value and momentum, Novacyt SA is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Novacyt SA share price forecast 2020?

Shares in Novacyt SA are currently priced at 760p. At that level they are trading at 90.04% premium to the analyst consensus target price of 399.92.

Analysts covering Novacyt SA currently have a consensus Earnings Per Share (EPS) forecast of 0.14 for the next financial year.

How can I tell whether the Novacyt SA share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Novacyt SA. Over the past six months, the relative strength of its shares against the market has been 0.126k%. At the current price of 760p, shares in Novacyt SA are trading at 93.09% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Novacyt SA PE Ratio?

The Novacyt SA PE ratio based on its reported earnings over the past 12 months is 14.94. The shares are currently trading at 760p.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Novacyt SA?

Novacyt SA's management team is headed by:

Jean-Pierre Crinelli - NED
Graham Mullis - CEO
Anthony Dyer - CFO
Ian Wilde - EXB
Andrew Heath - NID
Ruth Powell - EXB
Phillip Sefton - EXB
James Wakefield - NEC
Edwin Snape - NID
Juliet Thompson - NID
Steve Gibson - EXB
Wendy Karban - CHO
Paul Eros - EXB
Mandy Cowling - DIR
Who are the major shareholders of Novacyt SA?

Here are the top five shareholders of Novacyt SA based on the size of their shareholding:

Legal & General Investment Management Ltd. Investment Advisor/Hedge Fund
Percentage owned: 3.56% (2.52m shares)
Talence Gestion, SAS Investment Advisor
Percentage owned: 2.07% (1.46m shares)
Harbert Fund Advisors, Inc Investment Advisor/Hedge Fund
Percentage owned: 1.8% (1.27m shares)
Amiral Gestion S.A. Investment Advisor
Percentage owned: 0.98% (690k shares)
NOVA 2 Mutual Fund
Percentage owned: 0.98% (690k shares)
Similar to NCYT
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.